Last reviewed · How we verify

NCT05350384

An Unusual Association Between Pancreatic Cancer and Purtscher-like Retinopathy

Completed Last updated 28 April 2022
What this trial tests

trial testing Methylprednisolone in Purtscher Retinopathy in 1 participant. Completed in 1 November 2021.

Timeline
18 June 2021
Primary endpoint
31 July 2021
1 November 2021

Quick facts

Lead sponsorUniversity of Catania
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1
Start date18 June 2021
Primary completion31 July 2021
Estimated completion1 November 2021
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

University of Catania

Who can join

Eligibility, male only, with Purtscher Retinopathy or Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

AN UNUSUAL ASSOCIATION BETWEEN PANCREATIC CANCER AND PURTSCHER-LIKE RETINOPATHY

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. An unusual association between pancreatic cancer and Purtscher-like retinopathy: Presentation of a unique case.
    Intagliata E, Giugno S, Vizzini C, Cacciola RR, et al · · 2022 · cited 1× · PMID 35753234 · DOI 10.1016/j.ijscr.2022.107338

Verify or expand the search:

Other trials of Methylprednisolone

Trials testing the same drug.

Other University of Catania trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05350384.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing